Industry Research Reports

Home > Reports > Pharma & Healthcare > Antianginal Agents - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Antianginal Agents - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Industry: Pharma & Healthcare

Published: 2024-01-11

Pages: 168 Pages

Report ld: 2636191

Description
Table of Contents
Table of Figures
PDF Download

Description
Table of Contents
Table of Figures
PDF Download

Description

Antianginal agents is a term used to describe a wide variety of medicines that are used in the management of angina.

The global market for Antianginal Agents was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Antianginal Agents, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Antianginal Agents by region & country, by Type, and by Application.

The Antianginal Agents market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antianginal Agents.

Market Segmentation

Report Metric
Details
Report Title
Antianginal Agents - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Global Antianginal Agents Companies Covered
Teva, Merck, Pfizer, Mylan N.V., Elite Pharmaceutical Solution Inc., Pharmaoffer.com, AstraZeneca, ACETO, Nesher Pharmaceuticals, Taj pharmaceutical, Espero BioPharma, Hikma Pharmaceuticals, Athenex, Aurobindo Pharma, AMRI, Intas Pharmaceuticals, Glenmark Pharmaceuticals, Troikaa, Square Pharmaceuticals, Sun Pharmaceutical, Unique Pharmaceuticals, Ipca Laboratories, Sandoz, Globus Remedies, Shandong Fangming Pharmaceutical Group, ReYoung Pharmaceutical
Global Antianginal Agents Market, by Region
North America (U.S., Canada, Mexico)

Europe (Germany, France, UK, Italy, etc.)

Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)

South America (Brazil, etc.)

Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Antianginal Agents Market, Segment by Type
Nitrates

Beta Blockers

Calcium Channel Blockers
Global Antianginal Agents Market, Segment by Application
Hospital Pharmacies

Retail Pharmacies

Online Pharmacies
Forecast Units
USD million in value
Report Coverage
Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Antianginal Agents manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Antianginal Agents in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Antianginal Agents in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Table of Contents

 1 Market Overview
    1.1 Antianginal Agents Product Introduction
    1.2 Global Antianginal Agents Market Size Forecast
        1.2.1 Global Antianginal Agents Sales Value (2019-2030)
        1.2.2 Global Antianginal Agents Sales Volume (2019-2030)
        1.2.3 Global Antianginal Agents Sales Price (2019-2030)
    1.3 Antianginal Agents Market Trends & Drivers
        1.3.1 Antianginal Agents Industry Trends
        1.3.2 Antianginal Agents Market Drivers & Opportunity
        1.3.3 Antianginal Agents Market Challenges
        1.3.4 Antianginal Agents Market Restraints
    1.4 Assumptions and Limitations
    1.5 Study Objectives
    1.6 Years Considered

 2 Competitive Analysis by Company
    2.1 Global Antianginal Agents Players Revenue Ranking (2023)
    2.2 Global Antianginal Agents Revenue by Company (2019-2024)
    2.3 Global Antianginal Agents Players Sales Volume Ranking (2023)
    2.4 Global Antianginal Agents Sales Volume by Company Players (2019-2024)
    2.5 Global Antianginal Agents Average Price by Company (2019-2024)
    2.6 Key Manufacturers Antianginal Agents Manufacturing Base Distribution and Headquarters
    2.7 Key Manufacturers Antianginal Agents Product Offered
    2.8 Key Manufacturers Time to Begin Mass Production of Antianginal Agents
    2.9 Antianginal Agents Market Competitive Analysis
        2.9.1 Antianginal Agents Market Concentration Rate (2019-2024)
        2.9.2 Global 5 and 10 Largest Manufacturers by Antianginal Agents Revenue in 2023
        2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antianginal Agents as of 2023)
    2.10 Mergers & Acquisitions, Expansion

 3 Segmentation by Type
    3.1 Introduction by Type
        3.1.1 Nitrates
        3.1.2 Beta Blockers
        3.1.3 Calcium Channel Blockers
    3.2 Global Antianginal Agents Sales Value by Type
        3.2.1 Global Antianginal Agents Sales Value by Type (2019 VS 2023 VS 2030)
        3.2.2 Global Antianginal Agents Sales Value, by Type (2019-2030)
        3.2.3 Global Antianginal Agents Sales Value, by Type (%) (2019-2030)
    3.3 Global Antianginal Agents Sales Volume by Type
        3.3.1 Global Antianginal Agents Sales Volume by Type (2019 VS 2023 VS 2030)
        3.3.2 Global Antianginal Agents Sales Volume, by Type (2019-2030)
        3.3.3 Global Antianginal Agents Sales Volume, by Type (%) (2019-2030)
    3.4 Global Antianginal Agents Average Price by Type (2019-2030)

 4 Segmentation by Application
    4.1 Introduction by Application
        4.1.1 Hospital Pharmacies
        4.1.2 Retail Pharmacies
        4.1.3 Online Pharmacies
    4.2 Global Antianginal Agents Sales Value by Application
        4.2.1 Global Antianginal Agents Sales Value by Application (2019 VS 2023 VS 2030)
        4.2.2 Global Antianginal Agents Sales Value, by Application (2019-2030)
        4.2.3 Global Antianginal Agents Sales Value, by Application (%) (2019-2030)
    4.3 Global Antianginal Agents Sales Volume by Application
        4.3.1 Global Antianginal Agents Sales Volume by Application (2019 VS 2023 VS 2030)
        4.3.2 Global Antianginal Agents Sales Volume, by Application (2019-2030)
        4.3.3 Global Antianginal Agents Sales Volume, by Application (%) (2019-2030)
    4.4 Global Antianginal Agents Average Price by Application (2019-2030)

 5 Segmentation by Region
    5.1 Global Antianginal Agents Sales Value by Region
        5.1.1 Global Antianginal Agents Sales Value by Region: 2019 VS 2023 VS 2030
        5.1.2 Global Antianginal Agents Sales Value by Region (2019-2024)
        5.1.3 Global Antianginal Agents Sales Value by Region (2025-2030)
        5.1.4 Global Antianginal Agents Sales Value by Region (%), (2019-2030)
    5.2 Global Antianginal Agents Sales Volume by Region
        5.2.1 Global Antianginal Agents Sales Volume by Region: 2019 VS 2023 VS 2030
        5.2.2 Global Antianginal Agents Sales Volume by Region (2019-2024)
        5.2.3 Global Antianginal Agents Sales Volume by Region (2025-2030)
        5.2.4 Global Antianginal Agents Sales Volume by Region (%), (2019-2030)
    5.3 Global Antianginal Agents Average Price by Region (2019-2030)
    5.4 North America
        5.4.1 North America Antianginal Agents Sales Value, 2019-2030
        5.4.2 North America Antianginal Agents Sales Value by Country (%), 2023 VS 2030
    5.5 Europe
        5.5.1 Europe Antianginal Agents Sales Value, 2019-2030
        5.5.2 Europe Antianginal Agents Sales Value by Country (%), 2023 VS 2030
    5.6 Asia Pacific
        5.6.1 Asia Pacific Antianginal Agents Sales Value, 2019-2030
        5.6.2 Asia Pacific Antianginal Agents Sales Value by Country (%), 2023 VS 2030
    5.7 South America
        5.7.1 South America Antianginal Agents Sales Value, 2019-2030
        5.7.2 South America Antianginal Agents Sales Value by Country (%), 2023 VS 2030
    5.8 Middle East & Africa
        5.8.1 Middle East & Africa Antianginal Agents Sales Value, 2019-2030
        5.8.2 Middle East & Africa Antianginal Agents Sales Value by Country (%), 2023 VS 2030

 6 Segmentation by Key Countries/Regions
    6.1 Key Countries/Regions Antianginal Agents Sales Value Growth Trends, 2019 VS 2023 VS 2030
    6.2 Key Countries/Regions Antianginal Agents Sales Value
        6.2.1 Key Countries/Regions Antianginal Agents Sales Value, 2019-2030
        6.2.2 Key Countries/Regions Antianginal Agents Sales Volume, 2019-2030
    6.3 United States
        6.3.1 United States Antianginal Agents Sales Value, 2019-2030
        6.3.2 United States Antianginal Agents Sales Value by Type (%), 2023 VS 2030
        6.3.3 United States Antianginal Agents Sales Value by Application, 2023 VS 2030
    6.4 Europe
        6.4.1 Europe Antianginal Agents Sales Value, 2019-2030
        6.4.2 Europe Antianginal Agents Sales Value by Type (%), 2023 VS 2030
        6.4.3 Europe Antianginal Agents Sales Value by Application, 2023 VS 2030
    6.5 China
        6.5.1 China Antianginal Agents Sales Value, 2019-2030
        6.5.2 China Antianginal Agents Sales Value by Type (%), 2023 VS 2030
        6.5.3 China Antianginal Agents Sales Value by Application, 2023 VS 2030
    6.6 Japan
        6.6.1 Japan Antianginal Agents Sales Value, 2019-2030
        6.6.2 Japan Antianginal Agents Sales Value by Type (%), 2023 VS 2030
        6.6.3 Japan Antianginal Agents Sales Value by Application, 2023 VS 2030
    6.7 South Korea
        6.7.1 South Korea Antianginal Agents Sales Value, 2019-2030
        6.7.2 South Korea Antianginal Agents Sales Value by Type (%), 2023 VS 2030
        6.7.3 South Korea Antianginal Agents Sales Value by Application, 2023 VS 2030
    6.8 Southeast Asia
        6.8.1 Southeast Asia Antianginal Agents Sales Value, 2019-2030
        6.8.2 Southeast Asia Antianginal Agents Sales Value by Type (%), 2023 VS 2030
        6.8.3 Southeast Asia Antianginal Agents Sales Value by Application, 2023 VS 2030
    6.9 India
        6.9.1 India Antianginal Agents Sales Value, 2019-2030
        6.9.2 India Antianginal Agents Sales Value by Type (%), 2023 VS 2030
        6.9.3 India Antianginal Agents Sales Value by Application, 2023 VS 2030

 7 Company Profiles
    7.1 Teva
        7.1.1 Teva Company Information
        7.1.2 Teva Introduction and Business Overview
        7.1.3 Teva Antianginal Agents Sales, Revenue and Gross Margin (2019-2024)
        7.1.4 Teva Antianginal Agents Product Offerings
        7.1.5 Teva Recent Development
    7.2 Merck
        7.2.1 Merck Company Information
        7.2.2 Merck Introduction and Business Overview
        7.2.3 Merck Antianginal Agents Sales, Revenue and Gross Margin (2019-2024)
        7.2.4 Merck Antianginal Agents Product Offerings
        7.2.5 Merck Recent Development
    7.3 Pfizer
        7.3.1 Pfizer Company Information
        7.3.2 Pfizer Introduction and Business Overview
        7.3.3 Pfizer Antianginal Agents Sales, Revenue and Gross Margin (2019-2024)
        7.3.4 Pfizer Antianginal Agents Product Offerings
        7.3.5 Pfizer Recent Development
    7.4 Mylan N.V.
        7.4.1 Mylan N.V. Company Information
        7.4.2 Mylan N.V. Introduction and Business Overview
        7.4.3 Mylan N.V. Antianginal Agents Sales, Revenue and Gross Margin (2019-2024)
        7.4.4 Mylan N.V. Antianginal Agents Product Offerings
        7.4.5 Mylan N.V. Recent Development
    7.5 Elite Pharmaceutical Solution Inc.
        7.5.1 Elite Pharmaceutical Solution Inc. Company Information
        7.5.2 Elite Pharmaceutical Solution Inc. Introduction and Business Overview
        7.5.3 Elite Pharmaceutical Solution Inc. Antianginal Agents Sales, Revenue and Gross Margin (2019-2024)
        7.5.4 Elite Pharmaceutical Solution Inc. Antianginal Agents Product Offerings
        7.5.5 Elite Pharmaceutical Solution Inc. Recent Development
    7.6 Pharmaoffer.com
        7.6.1 Pharmaoffer.com Company Information
        7.6.2 Pharmaoffer.com Introduction and Business Overview
        7.6.3 Pharmaoffer.com Antianginal Agents Sales, Revenue and Gross Margin (2019-2024)
        7.6.4 Pharmaoffer.com Antianginal Agents Product Offerings
        7.6.5 Pharmaoffer.com Recent Development
    7.7 AstraZeneca
        7.7.1 AstraZeneca Company Information
        7.7.2 AstraZeneca Introduction and Business Overview
        7.7.3 AstraZeneca Antianginal Agents Sales, Revenue and Gross Margin (2019-2024)
        7.7.4 AstraZeneca Antianginal Agents Product Offerings
        7.7.5 AstraZeneca Recent Development
    7.8 ACETO
        7.8.1 ACETO Company Information
        7.8.2 ACETO Introduction and Business Overview
        7.8.3 ACETO Antianginal Agents Sales, Revenue and Gross Margin (2019-2024)
        7.8.4 ACETO Antianginal Agents Product Offerings
        7.8.5 ACETO Recent Development
    7.9 Nesher Pharmaceuticals
        7.9.1 Nesher Pharmaceuticals Company Information
        7.9.2 Nesher Pharmaceuticals Introduction and Business Overview
        7.9.3 Nesher Pharmaceuticals Antianginal Agents Sales, Revenue and Gross Margin (2019-2024)
        7.9.4 Nesher Pharmaceuticals Antianginal Agents Product Offerings
        7.9.5 Nesher Pharmaceuticals Recent Development
    7.10 Taj pharmaceutical
        7.10.1 Taj pharmaceutical Company Information
        7.10.2 Taj pharmaceutical Introduction and Business Overview
        7.10.3 Taj pharmaceutical Antianginal Agents Sales, Revenue and Gross Margin (2019-2024)
        7.10.4 Taj pharmaceutical Antianginal Agents Product Offerings
        7.10.5 Taj pharmaceutical Recent Development
    7.11 Espero BioPharma
        7.11.1 Espero BioPharma Company Information
        7.11.2 Espero BioPharma Introduction and Business Overview
        7.11.3 Espero BioPharma Antianginal Agents Sales, Revenue and Gross Margin (2019-2024)
        7.11.4 Espero BioPharma Antianginal Agents Product Offerings
        7.11.5 Espero BioPharma Recent Development
    7.12 Hikma Pharmaceuticals
        7.12.1 Hikma Pharmaceuticals Company Information
        7.12.2 Hikma Pharmaceuticals Introduction and Business Overview
        7.12.3 Hikma Pharmaceuticals Antianginal Agents Sales, Revenue and Gross Margin (2019-2024)
        7.12.4 Hikma Pharmaceuticals Antianginal Agents Product Offerings
        7.12.5 Hikma Pharmaceuticals Recent Development
    7.13 Athenex
        7.13.1 Athenex Company Information
        7.13.2 Athenex Introduction and Business Overview
        7.13.3 Athenex Antianginal Agents Sales, Revenue and Gross Margin (2019-2024)
        7.13.4 Athenex Antianginal Agents Product Offerings
        7.13.5 Athenex Recent Development
    7.14 Aurobindo Pharma
        7.14.1 Aurobindo Pharma Company Information
        7.14.2 Aurobindo Pharma Introduction and Business Overview
        7.14.3 Aurobindo Pharma Antianginal Agents Sales, Revenue and Gross Margin (2019-2024)
        7.14.4 Aurobindo Pharma Antianginal Agents Product Offerings
        7.14.5 Aurobindo Pharma Recent Development
    7.15 AMRI
        7.15.1 AMRI Company Information
        7.15.2 AMRI Introduction and Business Overview
        7.15.3 AMRI Antianginal Agents Sales, Revenue and Gross Margin (2019-2024)
        7.15.4 AMRI Antianginal Agents Product Offerings
        7.15.5 AMRI Recent Development
    7.16 Intas Pharmaceuticals
        7.16.1 Intas Pharmaceuticals Company Information
        7.16.2 Intas Pharmaceuticals Introduction and Business Overview
        7.16.3 Intas Pharmaceuticals Antianginal Agents Sales, Revenue and Gross Margin (2019-2024)
        7.16.4 Intas Pharmaceuticals Antianginal Agents Product Offerings
        7.16.5 Intas Pharmaceuticals Recent Development
    7.17 Glenmark Pharmaceuticals
        7.17.1 Glenmark Pharmaceuticals Company Information
        7.17.2 Glenmark Pharmaceuticals Introduction and Business Overview
        7.17.3 Glenmark Pharmaceuticals Antianginal Agents Sales, Revenue and Gross Margin (2019-2024)
        7.17.4 Glenmark Pharmaceuticals Antianginal Agents Product Offerings
        7.17.5 Glenmark Pharmaceuticals Recent Development
    7.18 Troikaa
        7.18.1 Troikaa Company Information
        7.18.2 Troikaa Introduction and Business Overview
        7.18.3 Troikaa Antianginal Agents Sales, Revenue and Gross Margin (2019-2024)
        7.18.4 Troikaa Antianginal Agents Product Offerings
        7.18.5 Troikaa Recent Development
    7.19 Square Pharmaceuticals
        7.19.1 Square Pharmaceuticals Company Information
        7.19.2 Square Pharmaceuticals Introduction and Business Overview
        7.19.3 Square Pharmaceuticals Antianginal Agents Sales, Revenue and Gross Margin (2019-2024)
        7.19.4 Square Pharmaceuticals Antianginal Agents Product Offerings
        7.19.5 Square Pharmaceuticals Recent Development
    7.20 Sun Pharmaceutical
        7.20.1 Sun Pharmaceutical Company Information
        7.20.2 Sun Pharmaceutical Introduction and Business Overview
        7.20.3 Sun Pharmaceutical Antianginal Agents Sales, Revenue and Gross Margin (2019-2024)
        7.20.4 Sun Pharmaceutical Antianginal Agents Product Offerings
        7.20.5 Sun Pharmaceutical Recent Development
    7.21 Unique Pharmaceuticals
        7.21.1 Unique Pharmaceuticals Company Information
        7.21.2 Unique Pharmaceuticals Introduction and Business Overview
        7.21.3 Unique Pharmaceuticals Antianginal Agents Sales, Revenue and Gross Margin (2019-2024)
        7.21.4 Unique Pharmaceuticals Antianginal Agents Product Offerings
        7.21.5 Unique Pharmaceuticals Recent Development
    7.22 Ipca Laboratories
        7.22.1 Ipca Laboratories Company Information
        7.22.2 Ipca Laboratories Introduction and Business Overview
        7.22.3 Ipca Laboratories Antianginal Agents Sales, Revenue and Gross Margin (2019-2024)
        7.22.4 Ipca Laboratories Antianginal Agents Product Offerings
        7.22.5 Ipca Laboratories Recent Development
    7.23 Sandoz
        7.23.1 Sandoz Company Information
        7.23.2 Sandoz Introduction and Business Overview
        7.23.3 Sandoz Antianginal Agents Sales, Revenue and Gross Margin (2019-2024)
        7.23.4 Sandoz Antianginal Agents Product Offerings
        7.23.5 Sandoz Recent Development
    7.24 Globus Remedies
        7.24.1 Globus Remedies Company Information
        7.24.2 Globus Remedies Introduction and Business Overview
        7.24.3 Globus Remedies Antianginal Agents Sales, Revenue and Gross Margin (2019-2024)
        7.24.4 Globus Remedies Antianginal Agents Product Offerings
        7.24.5 Globus Remedies Recent Development
    7.25 Shandong Fangming Pharmaceutical Group
        7.25.1 Shandong Fangming Pharmaceutical Group Company Information
        7.25.2 Shandong Fangming Pharmaceutical Group Introduction and Business Overview
        7.25.3 Shandong Fangming Pharmaceutical Group Antianginal Agents Sales, Revenue and Gross Margin (2019-2024)
        7.25.4 Shandong Fangming Pharmaceutical Group Antianginal Agents Product Offerings
        7.25.5 Shandong Fangming Pharmaceutical Group Recent Development
    7.26 ReYoung Pharmaceutical
        7.26.1 ReYoung Pharmaceutical Company Information
        7.26.2 ReYoung Pharmaceutical Introduction and Business Overview
        7.26.3 ReYoung Pharmaceutical Antianginal Agents Sales, Revenue and Gross Margin (2019-2024)
        7.26.4 ReYoung Pharmaceutical Antianginal Agents Product Offerings
        7.26.5 ReYoung Pharmaceutical Recent Development

 8 Industry Chain Analysis
    8.1 Antianginal Agents Industrial Chain
    8.2 Antianginal Agents Upstream Analysis
        8.2.1 Key Raw Materials
        8.2.2 Raw Materials Key Suppliers
        8.2.3 Manufacturing Cost Structure
    8.3 Midstream Analysis
    8.4 Downstream Analysis (Customers Analysis)
    8.5 Sales Model and Sales Channels
        8.5.1 Antianginal Agents Sales Model
        8.5.2 Sales Channel
        8.5.3 Antianginal Agents Distributors

 9 Research Findings and Conclusion

 10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
        10.1.2 Data Source
    10.2 Author Details
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Antianginal Agents Market Trends
    Table 2. Antianginal Agents Market Drivers & Opportunity
    Table 3. Antianginal Agents Market Challenges
    Table 4. Antianginal Agents Market Restraints
    Table 5. Global Antianginal Agents Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global Antianginal Agents Revenue Market Share by Company (2019-2024)
    Table 7. Global Antianginal Agents Sales Volume by Company (2019-2024) & (K Units)
    Table 8. Global Antianginal Agents Sales Volume Market Share by Company (2019-2024)
    Table 9. Global Market Antianginal Agents Price by Company (2019-2024) & (US$/Unit)
    Table 10. Key Manufacturers Antianginal Agents Manufacturing Base Distribution and Headquarters
    Table 11. Key Manufacturers Antianginal Agents Product Type
    Table 12. Key Manufacturers Time to Begin Mass Production of Antianginal Agents
    Table 13. Global Antianginal Agents Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antianginal Agents as of 2023)
    Table 15. Mergers & Acquisitions, Expansion Plans
    Table 16. Global Antianginal Agents Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 17. Global Antianginal Agents Sales Value by Type (2019-2024) & (US$ Million)
    Table 18. Global Antianginal Agents Sales Value by Type (2025-2030) & (US$ Million)
    Table 19. Global Antianginal Agents Sales Market Share in Value by Type (2019-2024) & (%)
    Table 20. Global Antianginal Agents Sales Market Share in Value by Type (2025-2030) & (%)
    Table 21. Global Antianginal Agents Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)
    Table 22. Global Antianginal Agents Sales Volume by Type (2019-2024) & (K Units)
    Table 23. Global Antianginal Agents Sales Volume by Type (2025-2030) & (K Units)
    Table 24. Global Antianginal Agents Sales Market Share in Volume by Type (2019-2024) & (%)
    Table 25. Global Antianginal Agents Sales Market Share in Volume by Type (2025-2030) & (%)
    Table 26. Global Antianginal Agents Price by Type (2019-2024) & (US$/Unit)
    Table 27. Global Antianginal Agents Price by Type (2025-2030) & (US$/Unit)
    Table 28. Global Antianginal Agents Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 29. Global Antianginal Agents Sales Value by Application (2019-2024) & (US$ Million)
    Table 30. Global Antianginal Agents Sales Value by Application (2025-2030) & (US$ Million)
    Table 31. Global Antianginal Agents Sales Market Share in Value by Application (2019-2024) & (%)
    Table 32. Global Antianginal Agents Sales Market Share in Value by Application (2025-2030) & (%)
    Table 33. Global Antianginal Agents Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)
    Table 34. Global Antianginal Agents Sales Volume by Application (2019-2024) & (K Units)
    Table 35. Global Antianginal Agents Sales Volume by Application (2025-2030) & (K Units)
    Table 36. Global Antianginal Agents Sales Market Share in Volume by Application (2019-2024) & (%)
    Table 37. Global Antianginal Agents Sales Market Share in Volume by Application (2025-2030) & (%)
    Table 38. Global Antianginal Agents Price by Application (2019-2024) & (US$/Unit)
    Table 39. Global Antianginal Agents Price by Application (2025-2030) & (US$/Unit)
    Table 40. Global Antianginal Agents Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 41. Global Antianginal Agents Sales Value by Region (2019-2024) & (US$ Million)
    Table 42. Global Antianginal Agents Sales Value by Region (2025-2030) & (US$ Million)
    Table 43. Global Antianginal Agents Sales Value by Region (2019-2024) & (%)
    Table 44. Global Antianginal Agents Sales Value by Region (2025-2030) & (%)
    Table 45. Global Antianginal Agents Sales Volume by Region (K Units): 2019 VS 2023 VS 2030
    Table 46. Global Antianginal Agents Sales Volume by Region (2019-2024) & (K Units)
    Table 47. Global Antianginal Agents Sales Volume by Region (2025-2030) & (K Units)
    Table 48. Global Antianginal Agents Sales Volume by Region (2019-2024) & (%)
    Table 49. Global Antianginal Agents Sales Volume by Region (2025-2030) & (%)
    Table 50. Global Antianginal Agents Average Price by Region (2019-2024) & (US$/Unit)
    Table 51. Global Antianginal Agents Average Price by Region (2025-2030) & (US$/Unit)
    Table 52. Key Countries/Regions Antianginal Agents Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 53. Key Countries/Regions Antianginal Agents Sales Value, (2019-2024) & (US$ Million)
    Table 54. Key Countries/Regions Antianginal Agents Sales Value, (2025-2030) & (US$ Million)
    Table 55. Key Countries/Regions Antianginal Agents Sales Volume, (2019-2024) & (K Units)
    Table 56. Key Countries/Regions Antianginal Agents Sales Volume, (2025-2030) & (K Units)
    Table 57. Teva Company Information
    Table 58. Teva Introduction and Business Overview
    Table 59. Teva Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 60. Teva Antianginal Agents Product Offerings
    Table 61. Teva Recent Development
    Table 62. Merck Company Information
    Table 63. Merck Introduction and Business Overview
    Table 64. Merck Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 65. Merck Antianginal Agents Product Offerings
    Table 66. Merck Recent Development
    Table 67. Pfizer Company Information
    Table 68. Pfizer Introduction and Business Overview
    Table 69. Pfizer Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 70. Pfizer Antianginal Agents Product Offerings
    Table 71. Pfizer Recent Development
    Table 72. Mylan N.V. Company Information
    Table 73. Mylan N.V. Introduction and Business Overview
    Table 74. Mylan N.V. Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 75. Mylan N.V. Antianginal Agents Product Offerings
    Table 76. Mylan N.V. Recent Development
    Table 77. Elite Pharmaceutical Solution Inc. Company Information
    Table 78. Elite Pharmaceutical Solution Inc. Introduction and Business Overview
    Table 79. Elite Pharmaceutical Solution Inc. Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 80. Elite Pharmaceutical Solution Inc. Antianginal Agents Product Offerings
    Table 81. Elite Pharmaceutical Solution Inc. Recent Development
    Table 82. Pharmaoffer.com Company Information
    Table 83. Pharmaoffer.com Introduction and Business Overview
    Table 84. Pharmaoffer.com Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 85. Pharmaoffer.com Antianginal Agents Product Offerings
    Table 86. Pharmaoffer.com Recent Development
    Table 87. AstraZeneca Company Information
    Table 88. AstraZeneca Introduction and Business Overview
    Table 89. AstraZeneca Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 90. AstraZeneca Antianginal Agents Product Offerings
    Table 91. AstraZeneca Recent Development
    Table 92. ACETO Company Information
    Table 93. ACETO Introduction and Business Overview
    Table 94. ACETO Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 95. ACETO Antianginal Agents Product Offerings
    Table 96. ACETO Recent Development
    Table 97. Nesher Pharmaceuticals Company Information
    Table 98. Nesher Pharmaceuticals Introduction and Business Overview
    Table 99. Nesher Pharmaceuticals Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 100. Nesher Pharmaceuticals Antianginal Agents Product Offerings
    Table 101. Nesher Pharmaceuticals Recent Development
    Table 102. Taj pharmaceutical Company Information
    Table 103. Taj pharmaceutical Introduction and Business Overview
    Table 104. Taj pharmaceutical Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 105. Taj pharmaceutical Antianginal Agents Product Offerings
    Table 106. Taj pharmaceutical Recent Development
    Table 107. Espero BioPharma Company Information
    Table 108. Espero BioPharma Introduction and Business Overview
    Table 109. Espero BioPharma Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 110. Espero BioPharma Antianginal Agents Product Offerings
    Table 111. Espero BioPharma Recent Development
    Table 112. Hikma Pharmaceuticals Company Information
    Table 113. Hikma Pharmaceuticals Introduction and Business Overview
    Table 114. Hikma Pharmaceuticals Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 115. Hikma Pharmaceuticals Antianginal Agents Product Offerings
    Table 116. Hikma Pharmaceuticals Recent Development
    Table 117. Athenex Company Information
    Table 118. Athenex Introduction and Business Overview
    Table 119. Athenex Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 120. Athenex Antianginal Agents Product Offerings
    Table 121. Athenex Recent Development
    Table 122. Aurobindo Pharma Company Information
    Table 123. Aurobindo Pharma Introduction and Business Overview
    Table 124. Aurobindo Pharma Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 125. Aurobindo Pharma Antianginal Agents Product Offerings
    Table 126. Aurobindo Pharma Recent Development
    Table 127. AMRI Company Information
    Table 128. AMRI Introduction and Business Overview
    Table 129. AMRI Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 130. AMRI Antianginal Agents Product Offerings
    Table 131. AMRI Recent Development
    Table 132. Intas Pharmaceuticals Company Information
    Table 133. Intas Pharmaceuticals Introduction and Business Overview
    Table 134. Intas Pharmaceuticals Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 135. Intas Pharmaceuticals Antianginal Agents Product Offerings
    Table 136. Intas Pharmaceuticals Recent Development
    Table 137. Glenmark Pharmaceuticals Company Information
    Table 138. Glenmark Pharmaceuticals Introduction and Business Overview
    Table 139. Glenmark Pharmaceuticals Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 140. Glenmark Pharmaceuticals Antianginal Agents Product Offerings
    Table 141. Glenmark Pharmaceuticals Recent Development
    Table 142. Troikaa Company Information
    Table 143. Troikaa Introduction and Business Overview
    Table 144. Troikaa Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 145. Troikaa Antianginal Agents Product Offerings
    Table 146. Troikaa Recent Development
    Table 147. Square Pharmaceuticals Company Information
    Table 148. Square Pharmaceuticals Introduction and Business Overview
    Table 149. Square Pharmaceuticals Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 150. Square Pharmaceuticals Antianginal Agents Product Offerings
    Table 151. Square Pharmaceuticals Recent Development
    Table 152. Sun Pharmaceutical Company Information
    Table 153. Sun Pharmaceutical Introduction and Business Overview
    Table 154. Sun Pharmaceutical Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 155. Sun Pharmaceutical Antianginal Agents Product Offerings
    Table 156. Sun Pharmaceutical Recent Development
    Table 157. Unique Pharmaceuticals Company Information
    Table 158. Unique Pharmaceuticals Introduction and Business Overview
    Table 159. Unique Pharmaceuticals Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 160. Unique Pharmaceuticals Antianginal Agents Product Offerings
    Table 161. Unique Pharmaceuticals Recent Development
    Table 162. Ipca Laboratories Company Information
    Table 163. Ipca Laboratories Introduction and Business Overview
    Table 164. Ipca Laboratories Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 165. Ipca Laboratories Antianginal Agents Product Offerings
    Table 166. Ipca Laboratories Recent Development
    Table 167. Sandoz Company Information
    Table 168. Sandoz Introduction and Business Overview
    Table 169. Sandoz Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 170. Sandoz Antianginal Agents Product Offerings
    Table 171. Sandoz Recent Development
    Table 172. Globus Remedies Company Information
    Table 173. Globus Remedies Introduction and Business Overview
    Table 174. Globus Remedies Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 175. Globus Remedies Antianginal Agents Product Offerings
    Table 176. Globus Remedies Recent Development
    Table 177. Shandong Fangming Pharmaceutical Group Introduction and Business Overview
    Table 178. Shandong Fangming Pharmaceutical Group Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 179. Shandong Fangming Pharmaceutical Group Antianginal Agents Product Offerings
    Table 180. Shandong Fangming Pharmaceutical Group Recent Development
    Table 181. Shandong Fangming Pharmaceutical Group Company Information
    Table 182. ReYoung Pharmaceutical Company Information
    Table 183. ReYoung Pharmaceutical Introduction and Business Overview
    Table 184. ReYoung Pharmaceutical Antianginal Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 185. ReYoung Pharmaceutical Antianginal Agents Product Offerings
    Table 186. ReYoung Pharmaceutical Recent Development
    Table 187. Key Raw Materials Lists
    Table 188. Raw Materials Key Suppliers Lists
    Table 189. Antianginal Agents Downstream Customers
    Table 190. Antianginal Agents Distributors List
    Table 191. Research Programs/Design for This Report
    Table 192. Key Data Information from Secondary Sources
    Table 193. Key Data Information from Primary Sources
List of Figures
    Figure 1. Antianginal Agents Product Picture
    Figure 2. Global Antianginal Agents Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Antianginal Agents Sales Value (2019-2030) & (US$ Million)
    Figure 4. Global Antianginal Agents Sales Volume (2019-2030) & (K Units)
    Figure 5. Global Antianginal Agents Sales Price (2019-2030) & (US$/Unit)
    Figure 6. Antianginal Agents Report Years Considered
    Figure 7. Global Antianginal Agents Players Revenue Ranking (2023) & (US$ Million)
    Figure 8. Global Antianginal Agents Players Sales Volume Ranking (2023) & (K Units)
    Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Antianginal Agents Revenue in 2023
    Figure 10. Antianginal Agents Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 11. Nitrates Picture
    Figure 12. Beta Blockers Picture
    Figure 13. Calcium Channel Blockers Picture
    Figure 14. Global Antianginal Agents Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 15. Global Antianginal Agents Sales Value Market Share by Type, 2023 & 2030
    Figure 16. Global Antianginal Agents Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)
    Figure 17. Global Antianginal Agents Sales Volume Market Share by Type, 2023 & 2030
    Figure 18. Global Antianginal Agents Price by Type (2019-2030) & (US$/Unit)
    Figure 19. Product Picture of Hospital Pharmacies
    Figure 20. Product Picture of Retail Pharmacies
    Figure 21. Product Picture of Online Pharmacies
    Figure 22. Global Antianginal Agents Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 23. Global Antianginal Agents Sales Value Market Share by Application, 2023 & 2030
    Figure 24. Global Antianginal Agents Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)
    Figure 25. Global Antianginal Agents Sales Volume Market Share by Application, 2023 & 2030
    Figure 26. Global Antianginal Agents Price by Application (2019-2030) & (US$/Unit)
    Figure 27. North America Antianginal Agents Sales Value (2019-2030) & (US$ Million)
    Figure 28. North America Antianginal Agents Sales Value by Country (%), 2023 VS 2030
    Figure 29. Europe Antianginal Agents Sales Value (2019-2030) & (US$ Million)
    Figure 30. Europe Antianginal Agents Sales Value by Country (%), 2023 VS 2030
    Figure 31. Asia Pacific Antianginal Agents Sales Value (2019-2030) & (US$ Million)
    Figure 32. Asia Pacific Antianginal Agents Sales Value by Country (%), 2023 VS 2030
    Figure 33. South America Antianginal Agents Sales Value (2019-2030) & (US$ Million)
    Figure 34. South America Antianginal Agents Sales Value by Country (%), 2023 VS 2030
    Figure 35. Middle East & Africa Antianginal Agents Sales Value (2019-2030) & (US$ Million)
    Figure 36. Middle East & Africa Antianginal Agents Sales Value by Country (%), 2023 VS 2030
    Figure 37. Key Countries/Regions Antianginal Agents Sales Value (%), (2019-2030)
    Figure 38. Key Countries/Regions Antianginal Agents Sales Volume (%), (2019-2030)
    Figure 39. United States Antianginal Agents Sales Value, (2019-2030) & (US$ Million)
    Figure 40. United States Antianginal Agents Sales Value by Type (%), 2023 VS 2030
    Figure 41. United States Antianginal Agents Sales Value by Application (%), 2023 VS 2030
    Figure 42. Europe Antianginal Agents Sales Value, (2019-2030) & (US$ Million)
    Figure 43. Europe Antianginal Agents Sales Value by Type (%), 2023 VS 2030
    Figure 44. Europe Antianginal Agents Sales Value by Application (%), 2023 VS 2030
    Figure 45. China Antianginal Agents Sales Value, (2019-2030) & (US$ Million)
    Figure 46. China Antianginal Agents Sales Value by Type (%), 2023 VS 2030
    Figure 47. China Antianginal Agents Sales Value by Application (%), 2023 VS 2030
    Figure 48. Japan Antianginal Agents Sales Value, (2019-2030) & (US$ Million)
    Figure 49. Japan Antianginal Agents Sales Value by Type (%), 2023 VS 2030
    Figure 50. Japan Antianginal Agents Sales Value by Application (%), 2023 VS 2030
    Figure 51. South Korea Antianginal Agents Sales Value, (2019-2030) & (US$ Million)
    Figure 52. South Korea Antianginal Agents Sales Value by Type (%), 2023 VS 2030
    Figure 53. South Korea Antianginal Agents Sales Value by Application (%), 2023 VS 2030
    Figure 54. Southeast Asia Antianginal Agents Sales Value, (2019-2030) & (US$ Million)
    Figure 55. Southeast Asia Antianginal Agents Sales Value by Type (%), 2023 VS 2030
    Figure 56. Southeast Asia Antianginal Agents Sales Value by Application (%), 2023 VS 2030
    Figure 57. India Antianginal Agents Sales Value, (2019-2030) & (US$ Million)
    Figure 58. India Antianginal Agents Sales Value by Type (%), 2023 VS 2030
    Figure 59. India Antianginal Agents Sales Value by Application (%), 2023 VS 2030
    Figure 60. Antianginal Agents Industrial Chain
    Figure 61. Antianginal Agents Manufacturing Cost Structure
    Figure 62. Channels of Distribution (Direct Sales, and Distribution)
    Figure 63. Bottom-up and Top-down Approaches for This Report
    Figure 64. Data Triangulation
    Figure 65. Key Executives Interviewed

Description

Antianginal agents is a term used to describe a wide variety of medicines that are used in the management of angina.

The global market for Antianginal Agents was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

Market Segmentation